Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse effect that causes delayed treatment and poor prognosis among colorectal cancer (CRC) patients. However, its mechanism remains elusive, and no effective treatment is available. We employed a prospective cohort study of adult patien...

Full description

Saved in:
Bibliographic Details
Published in:Theranostics 2021-01, Vol.11 (10), p.4672-4687
Main Authors: Chen, Szu-Jung, Chen, Li-Hsien, Yeh, Yu-Min, Lin, Chou-Ching K, Lin, Peng-Chan, Huang, Han-Wei, Shen, Meng-Ru, Lin, Bo-Wen, Lee, Jeng-Chang, Lee, Cheng-Che, Lee, Yueh-Feng, Chiang, Huai-Chueh, Chang, Jang-Yang
Format: Article
Language:English
Subjects:
Biomarkers
Chemotherapy
CRISPR
Cytokines
Females
Laboratory animals
Mutation
Peripheral neuropathy
Questionnaires
Research Paper
Stem cells
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse effect that causes delayed treatment and poor prognosis among colorectal cancer (CRC) patients. However, its mechanism remains elusive, and no effective treatment is available. We employed a prospective cohort study of adult patients with pathologically confirmed stage III CRC receiving adjuvant chemotherapy with an oxaliplatin-based regimen for investigating OIPN. To further validate the clinical manifestations and identify a potential therapeutic strategy, animal models, and studies on the mechanism of OIPN were applied. Our work found that (1) consistent with clinical findings, OIPN was observed in animal models. Targeting the enzymatic activity of cathepsin S (CTSS) by pharmacological blockade and gene deficiency strategy alleviates the manifestations of OIPN. (2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca entry homeostasis. (3) The cytokine array demonstrated an increase in anti-inflammatory cytokines and suppression of proinflammatory cytokines in mice treated with RJW-58. (4) Mechanistically, inhibiting CTSS facilitated olfactory receptors transcription factor 1 release from P300/CBP binding, which enhanced binding to the interleukin-10 (IL-10) promoter region, driving IL-10 downstream signaling pathway. (5) Serum CTSS expression is increased in CRC patients with oxaliplatin-induced neurotoxicity. We highlighted the critical role of CTSS in OIPN, which provides a therapeutic strategy for the common adverse side effects of oxaliplatin.
ISSN:1838-7640
1838-7640
DOI:10.7150/thno.54793